XML 63 R27.htm IDEA: XBRL DOCUMENT
v3.22.4

Fourth Quarter Financial Data (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Fourth Quarter Financial Data (Unaudited) [Abstract] |
Fourth Quarter Financial Data (Unaudited) | The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized fourth quarter data for 2022 and 2021 are as follows (in thousands, except per share data).
Three Months Ended December 31, |  | 2022 |  |  | 2021 |
Revenue (1) |  | $ | 151,890 |  |  | $ | 440,006 |
Operating expenses (2) |  | $ | 359,909 |  |  | $ | 219,403 |
Income (loss) from operations |  | $ | (208,019 | ) |  | $ | 220,603 |
Net income (loss) (3) |  | $ | (52,430 | ) |  | $ | 224,613 |
Basic net income (loss) per share (4) (5) |  | $ | (0.37 | ) |  | $ | 1.59 |
Diluted net income (loss) per share (4) (6) |  | $ | (0.37 | ) |  | $ | 1.41 |
________________
(1) | Revenue was lower in the three months ended December 31, 2022 compared to the same period in 2021 due to the $200 million we earned in the fourth quarter of 2021 from AstraZeneca to jointly develop and commercialize eplontersen.
(2) | Operating expenses were higher in the three months ended December 31, 2022 compared to the same period in 2021 primarily due to the $80 million upfront payment we made for our collaboration with Metagenomi in the fourth quarter of 2022.
(3) | Our net loss for the three months ended December 31, 2022 includes the $150.1 million gain we recognized from the sale and leaseback transaction for our headquarters in Carlsbad, California.
(4) | We compute net income (loss) per share independently for each quarter during the year.
(5) | As discussed in Note 1, Organization and Significant Accounting Policies, we compute basic net income (loss) per share by dividing the total net income (loss) by our weighted-average number of common shares outstanding during the period.
(6) | We had net income for the fourth quarter of 2021. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period as follows (in thousands except per share amounts):
Three Months Ended December 31, 2021 |  | Income (Numerator) |  |  | Shares (Denominator) |  |  | Per-Share Amount |
Net income available to Ionis common stockholders |  | $ | 224,612 |  |  |  | 141,205 |  |  | $ | 1.59 |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |  |
Shares issuable upon exercise of stock options |  |  | — |  |  |  | 46 |  |  |  |  |
Shares issuable upon restricted stock award issuance |  |  | — |  |  |  | 1,065 |  |  |  |  |
Shares issuable related to our ESPP |  |  | — |  |  |  | 34 |  |  |  |  |
Shares issuable related to our 0 percent convertible notes |  |  | 777 |  |  |  | 10,936 |  |  |  |  |
Shares issuable related to our 0.125 percent convertible notes |  |  | 716 |  |  |  | 6,590 |  |  |  |  |
Shares issuable related to our 1 percent convertible notes |  |  | 105 |  |  |  | 464 |  |  |  |  |
Income available to Ionis common stockholders, plus assumed conversions |  | $ | 226,210 |  |  |  | 160,340 |  |  | $ | 1.41 |

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration